Compare Gilead Sciences, Inc. (GILD) vs Oracle Corporation (ORCL) Price & Performance

Gilead Sciences, Inc.Trade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Oracle Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.39 (market cap $168.35B), while Oracle Corporation trades at $148.32 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 2.5× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

	GILD	ORCL
Market Cap	$168.35B	$419.05B
Sector	Health	Technology
52-Week High	$155.80	$328.33
52-Week Low	$110.56	$114.99
Enterprise Value	$191.42B	$548.30B
Dividend Yield	2.42%	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Oracle Corporation

Oracle (ORCL) trades at $145.45, down 1.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 beating expectations of $1.96, and fundamentals show robust revenue growth, reaching $57.4 billion in 2025, and high profitability with a net margin of 25.37%. Recent news highlights Oracle's AI infrastructure growth and a legal investigation into insider conduct.

Oracle's outlook is positive due to AI-driven demand and consistent earnings outperformance, supported by a consensus analyst price target of $253.63. Key risks include high valuation multiples, rising debt levels, and competitive pressures in cloud services. The stock offers growth potential but requires monitoring of execution risks and market sentiment shifts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

ORCL

Nebius shares jump 3.7% as NVIDIA backs $500B AI cloud fund, Oracle slips amid competitive pressure.24/7 Wall Street · 19 hours agoBullish Oracle poised for 40% gain as AI cloud growth and backlog surge drive bullish outlook24/7 Wall Street · 22 hours agoBullish Oracle launches AI-powered HR tools in Fusion Cloud to boost workforce development and talent management.PRNewsWire · 23 hours agoBullish View details →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.